Introduction
Atrial fibrillation (AF) confers a substantial risk of mortality and morbidity from stroke and thrombo-embolism, and this common cardiac arrhythmia represents a major healthcare burden in Europe. 1 Stroke prevention is central to the management of AF patients, with the 2012 focused update of the European Society of Cardiology (ESC) guidelines 2 recommending oral anticoagulation (OAC) using well-controlled adjusted dose vitamin K antagonists (VKAs, e.g. warfarin) or non-VKA oral anticoagulants (NOACs, previously referred to as new or novel OACs 3 ) for patients with AF and ≥1 stroke risk factor(s). Also, these guidelines strongly advocate a clinical practice shift so that the initial decision step now is the identification of 'truly low risk' patients, essentially those aged ,65 years without any stroke risk factor (both male and female), who do not need any antithrombotic therapy. 2 The ESC guidelines also recommend the use of the CHA 2 DS 2 -VASc score 4 for stroke risk assessment, and define 'low-risk' patients as those with a CHA 2 DS 2 -VASc score ¼ 0 (males) or score ¼ 1 (females). Subsequent to this initial step of identifying the low-risk patients, effective stroke prevention (which is essentially OAC) can then be offered to AF patients with ≥1 stroke risk factor(s), with treatment decisions made in consultation with patients and incorporating their preferences.
In everyday clinical practice, over 80% of all patients with AF have an indication for OAC, and vascular disease co-exists in 30% of them. 5 -7 With an estimated prevalence of AF of 1-2% and 20%
of these requiring percutaneous cardiovascular interventions over time, 8 1-2 million AF patients in Europe who are on OAC may undergo percutaneous coronary interventions (PCI), usually including stenting. Almost all of these patients will have an indication for continuous OAC. Considerable variation in European clinical practice for the management of such patients is evident. 9 Acute coronary syndromes (ACS), including unstable angina/ non-ST segment elevation myocardial infarction (NSTE-ACS) and ST-segment elevation myocardial infarction (STEMI), constitute another cardiovascular disease entity with associated risks of mortality and morbidity from myocardial infarction (MI), heart failure, and ventricular arrhythmias. Antithrombotic therapy, with dual antiplatelet therapy consisting of low-dose acetylsalicylic acid and P2Y 12 inhibitors with ticagrelor or prasugrel being recommended as first line, is the mainstay to reduce the risk of recurrent ischaemic events during the first year after the acute event. In addition, an early invasive strategy in case of NSTE-ACS and primary PCI in case of STEMI with revascularization of culprit lesions are the current standard of care in the management of patients with ACS. 10 A particular challenge in terms of antithrombotic treatment are patients who present with both AF and ACS, 11 especially since such patients are at high risk for cardiovascular mortality and morbidity. 12 As with the use of any antithrombotic drug, clinicians need to balance the risks of ischaemic stroke and thrombo-embolism, recurrent cardiac ischaemia or MI and/or stent thrombosis, and bleeding. In 2010, the European Society of Cardiology (ESC) Working Group on Thrombosis published a consensus document, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Coronary Intervention (EAPCI), to address the management aspects of this complex clinical scenario. 11 This was followed by a North American consensus document, which had many similarities in management approaches. 13, 14 Since 2010, substantial changes are now evident in stroke prevention in AF, with the introduction of NOACs and greater attention to quality of anticoagulation control [as reflected by average time in the therapeutic range (TTR) of the international normalized ratio (INR)]. 15 Also, new generation drug-eluting stents (DESs) are available which may be less thrombogenic, and additional interventional procedures are being undertaken, such as transcathether aortic valve implantation (TAVI) or percutaneous mitral valve repair, whereby the presence or development of AF can predispose to thrombo-embolism. 16, 17 Bridging therapy and the management of anticoagulated AF patients undergoing surgical or other procedures remains a management issue with expert guidance substituting for controlled trial data especially in patients taking NOACs. 18, 19 For this update, the Working Group on Thrombosis of the ESC convened a Task Force, with representation from EHRA, EAPCI, and the Acute Cardiovascular Care Association (ACCA), endorsed by the Heart Rhythm Society (HRS), and the Asia-Pacific Heart Rhythm Society (APHRS), with the remit to comprehensively review the published evidence available since the 2010 document, to publish a joint consensus document on the optimal antithrombotic therapy management in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions and to provide up-to-date recommendations for use in clinical practice.
For the purposes of this consensus document, AF will be defined as 'non-valvular AF',-that is, AF in the absence of prosthetic mechanical heart valves, or 'haemodynamically significant valve disease'. The latter refers to where the valve lesion (e.g. mitral stenosis) is severe enough to warrant intervention (e.g. surgery or percutaneous) or where it would have an impact on the patient's survival or well-being. Indeed, haemodynamically significant valve disease was generally excluded from the recent randomized trials of stroke prevention in AF: for example, the RE-LY trial excluded patients with 'severe heart valve disorder', whereas the ROCKET-AF trial excluded those with 'haemodynamically significant mitral valve stenosis' and the ARISTOTLE trial excluded those with 'moderate or severe mitral stenosis'. 20 -22 Overview of additional published data since 2010 on the topic of management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting
To address additional published data, we performed an overview of data published since the 2010 consensus document. These data are summarized in this section, which should be considered as complementary to the evidence tables published in the 2010 consensus document.
Cohort studies
Since 2010, various registries have again demonstrated the considerable heterogeneity in the combinations (and duration) of different antithrombotic drugs used in AF patients 23 -52 ( Table 1) . Notably, these patients are at high risk of both thrombotic and bleeding complications. 53 Most of the available data are still based on small, often single-centre and retrospective patient cohorts, or derive from subgroup analyses of patients enrolled in controlled trials of OAC. Despite these limitations, some guidance can be taken from the available data. In general, there is a benefit of continued OAC in preventing thrombotic events, and in some studies even reductions in mortality. Furthermore, there is evidence that continuation of OAC used for chronic therapy, rather than switching or 'bridging' to other anticoagulants, confers a lower risk for severe bleeding events. Despite the heterogeneity, there is sufficient evidence that OAC should not be interrupted in patients with AF suffering from an ACS. This benefit is maintained despite good evidence of an increased bleeding rate in patients taking OAC and antiplatelet agents compared with those on OAC alone, 43, 54 illustrating the higher relative risk of thrombo-embolic and thrombotic complications in these cohorts. Hence, 'dual therapy' (OAC + one antiplatelet agent) seems required, and possibly 'triple therapy' might be advisable, mainly in patients at high risk for thrombo-embolic ischaemic complications. Nonetheless, many unanswered questions remain resulting from the limitations of these types of registries, such as changes in the antithrombotic regimen over time, unknown duration of each type of antithrombotic drug, and unknown INR control (for those receiving VKAs), or even potential residual confounding arising from clinical characteristics, cessation of antithrombotic therapies in case of bleeding and different antithrombotic therapy indications.
Randomized controlled trials
Since publication of the 2010 consensus document, one controlled trial, the WOEST (What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing) trial 55 compared dual therapy (VKA plus clopidogrel) to triple therapy (VKA plus aspirin and clopidogrel) in 573 patients taking long-term OAC who received a coronary stent. The trial was powered to detect differences in the primary end-point of any (e.g. TIMI major plus minor) bleeding event within 1 year of follow-up. Combination therapy with OAC and clopidogrel was associated with less total bleeding complications (without significant differences in major bleeds), with no detectable increase in the rate of thrombotic events, especially stent thrombosis. Furthermore, there was a significant reduction in mortality at 12 months with dual therapy (Table 1) .
There are some important issues that may limit the conclusions of the WOEST trial: only 69% of patients received OAC due to AF. Most of the patients underwent elective PCI (70-75%), and the femoral approach was used in 74%, increasing access site bleeding. Furthermore, the differences between dual and triple therapy for the primary end-point of 'all bleeding' were driven by minor bleeding events, proton pump inhibitors (PPIs) were not used routinely and triple therapy was continued for 12 months (and thus, the increased risk of bleeding is unsurprising). Both the European and North American consensus documents, in principle, recommend duration of triple therapy for the shortest time necessary, although there are some differences between European and North American guidelines. 53, 56 Finally, the WOEST trial population size was too small to meaningfully assess major efficacy outcomes such as stent thrombosis or death.
Although it might be premature to abandon aspirin after stent implantation in AF patients requiring OAC based solely on the results of WOEST, dual therapy with OAC and clopidogrel may be considered as an alternative to triple therapy in selected AF patients at low risk of stent thrombosis/recurrent cardiac events.
Ongoing randomized controlled trials and registries
Two randomized trials and one multinational registry are currently testing different antithrombotic combinations for patients on OAC therapy who require stent implantation.
The ISAR-TRIPLE (Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation, clinicaltrials.gov id NCT00776633 [(http://clinicaltrials.gov/show/NCT00776633)] trial will address the hypothesis that reducing the length of clopidogrel therapy (75 mg o.d.) from 6 months to 6 weeks (in addition to aspirin and OAC) following implantation of a DES is associated with a reduced net composite end-point of death, MI, definite stent thrombosis, stroke, or major bleeding at 9 months.
The 52, 58 and the increased use of radial access for PCI, very large trials are needed to detect small differences between antithrombotic regimes in this patient cohort. The use of NOACs in the antithrombotic management of AF patients undergoing coronary stenting is a subject of continued interest, with clinical trials ongoing or being planned, as will be discussed further in the section 'Non-VKA oral anticoagulants'.
Non-VKA oral anticoagulants
The potential role of NOACs for patients with ACS and AF has not been directly assessed, since AF patients requiring OAC were systematically excluded from recent ACS trials, and conversely, patients with recent ACS were likely to have been excluded from phase III stroke prevention trials in AF patients.
The data available in the literature dealing with the most appropriate management of patients with AF and ACS and/or undergoing PCI come from different sources.
First, there are data on the effects of concomitant prescription of NOACs and antiplatelet drugs derived from post hoc analyses of randomized controlled trials (RCTs) of NOACs in non-valvular AF patients, 59 as well as data on patient outcomes from RCTs of NOACs and antiplatelets in ACS/PCI patients 60 -64 ( Table 2) . Where a NOAC is used in combination with clopidogrel and/or low-dose aspirin, the lower tested dose for stroke prevention in AF (that is, dabigatran 110 mg b.i.d., rivaroxaban 15 mg o.d. or apixaban 2.5 mg b.i.d.) should be considered, to minimize the risks of bleeding. However, dabigatran 110 b.i.d. was one intervention arm of the RE-LY trial, and thus, was tested among all eligible patients and may be considered on its own merits. On the other side, rivaroxaban 15 mg o.d. or apixaban 2.5 mg b.i.d. were given as a dose adjustment based on patient characteristics, and hence, prescribed to only a minority subset of the NOAC intervention arm. Thus, the lower doses may not necessarily provide adequate antithrombotic protection for AF in patients without the clinical features used for dose adjustment. Secondly, further evidence comes from data on the risk of MI associated with NOACs, derived from RCTs of NOACs vs. warfarin or aspirin in non-valvular AF, including the original analyses from primary reports of the RCTs, 20 -22,65,66 post hoc analyses or meta-analyses (the latter, pooling some data from RCTs, were not related to non-valvular AF patients), and 'real-life' nationwide AF patient data 67 -69 (see Supplementary material online, Table w1 ). In the meta-analysis of dabigatran trials reported by Uchino and Hernandez, 67 a significantly higher rate of MI was reported by using dabigatran vs. warfarin (HR: 1.33, 95% CI: 1.03-1.71). In the RE-LY data, the absolute increase of MI risk reported in the first analysis was very low (0.19-0.21%/year) 20 and was not confirmed to be significant after re-analysis of the data with the inclusion of silent MIs. 70 Moreover, the net clinical benefit of dabigatran over warfarin was maintained in AF patients with a previous MI, and no significant increase in the risk of the composite end-point of coronary and cardiac events (MI, unstable angina, cardiac arrest, and cardiac death) was found in patients treated with dabigatran vs. warfarin. 71 The most recent meta-analysis 72 of NOACs trials of AF, including the ENGAGE-AF trial, 66 found no significant difference in MI between NOACs (dabigatran and oral Factor Xa inhibitors in combination) and warfarin, but low dose regimes (dabigatran 110 mg b.i.d. and low-dose edoxaban) were associated with a 25% increase in MIs compared with warfarin in populations at low risk of recurrent events. It is unclear whether these effects also pertain to cohorts of ACS patients, where reinfarction is a common entity (e.g. ATLAS, 62 APPRAISE II 64 ). The debate on the small difference in MIs with dabigatran as reported in the first RE-LY analysis and the meta-analysis from Uchino and Hernandez 67 in patients who were stable at therapy initiation may simply be a reflection of the better protective effect of well-controlled warfarin against MI compared with NOACs. 73 The rates of MI in randomized trials in AF patients treated with NOACs, as well as the TTR of warfarin-treated patients is summarized in the Supplementary material online, Table w2 . In ACTIVE-W, for example, there were numerically more MIs in aspirin-clopidogrel treated AF patients compared with warfarin. 74 In the North
American subgroup of ROCKET-AF (mean TTR 64%), there were numerically more MIs in the rivaroxaban-treated patients (see Supplementary material online, Table w2 ). In the RE-LY trial, the annual rates of MI in the warfarin arm were 0.72 and 0.49%, with TTRs of ,65 and ≥65%, respectively. 75 A numerical increase in MI was also noted in AF patients from the ENGAGE TIMI 48 trial with low-dose edoxaban vs. warfarin (0.89 vs. 0.75%), but not with high dose edoxaban (0.70 vs. 0.75%) (see Supplementary material online, Table w2 ). 66 The HOKUSAI trial of edoxaban for venous thombo-embolism treatment found a numerical increase in MIs in edoxaban treated patients compared with those on warfarin (0.5 vs. 0.3%) (see Supplementary material online, Table w2 ).
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While conducted in non-AF patients, both ATLAS-TIMI 51 (comparing rivaroxaban in a low-dose BID regimen to placebo 62 ) and APPRAISE II (full-dose apixaban vs. placebo 64 ) demonstrated that adding a NOAC to dual antiplatelet therapy reduces reinfarction rates (APPRAISE II: 0.4%; ATLAS: 1.1%) compared with DAPT alone.
An analysis of the current literature (see Supplementary material online, Tables w1 and w2) allows some considerations on the potential role and risk -benefit ratio of NOACs in patients with ACS and/or PCI/stenting with subsequent need for additional anti-platelet therapy: † Historical data suggest that VKAs provide better protection against re-infarction than aspirin, albeit in a pre-statin and largely pre-PCI era. † Dabigatran increases the risk of bleeding, especially lower gastrointestinal tract bleeding, in the setting of ACS, and this occurs even at doses below those proven to be beneficial by reducing the risk of stroke in AF patients (e.g. below 110 mg b.i.d.). However, the overall benefit of dabigatran in patients undergoing PCI or those AF patients with concomitant aspirin use was maintained in the RE-LY trial population. † Apixaban at the dose that is beneficial in stroke prevention in AF patients (5 mg b.i.d.) increases the risk of bleeding when added to dual antiplatelet therapy and does not exert additional benefits against recurrent coronary events. However, the overall benefit of apixaban vs. warfarin was maintained in the ARISTOTLE trial irrespective of concomitant aspirin use. 77 † In ROCKET AF, AF patients with prior MI assigned to rivaroxaban had a numerical (non-significant) reduction of ischaemic cardiac events. 78 A series of measures can be applied to reduce the risk of bleeding in this setting in general, such as using low doses of aspirin (75 -100 mg o.d., which is the standard of care in Europe anyway); use of clopidogrel as the preferred P2Y 12 inhibitor instead of the more potent ticagrelor or prasugrel; use of bare-metal stents (BMS), thus minimizing the required duration of triple therapy, and the use of the radial approach, thus minimizing the risk of access site bleeding. 19 However, it is uncertain whether BMS use requires a shorter duration of dual antiplatelet therapy than new generation DES. Indeed late stent thrombosis (1 -12 months) is a recognized issue with BMS similar to DES. 82, 83 New data on dual antiplatelet therapy cessation also shows no difference between BMS and DES, especially with new generation stents. 84, 85 New generation DES (or BMS) would also be preferred over first generation DES, the latter being least preferred. 86 While it is impossible to extrapolate the results of the ACS trials in non-AF patients to patients with AF and ACS, an improved assessment of the role of NOACs in AF patients with ACS and/or PCI with stenting can be obtained from prospective trials. At present, the optimal NOAC regimen for patients with AF and ACS or undergoing PCI has not been addressed by a RCT.
At the time of writing, two NOAC trials are ongoing or planned. The PIONEER AF-PCI trial [NCT01651780 (http://clinicaltrials. gov/ct2/show/NCT01651780)] mainly addresses safety in terms of clinically significant bleeding of two different treatment strategies and doses of rivaroxaban (2.5 mg b.i.d. followed by 15 mg q.d. or 10 mg q.d. in subjects with moderate renal impairment) in comparison with a dose-adjusted oral VKA treatment strategy in subjects with AF undergoing PCI. In addition, all patients will receive either single or dual antiplatelet therapy. This trial will also study the more potent platelet inhibitors prasugrel and ticagrelor in combination with OAC. However, PIONEER -AF-PCI is not powered to detect differences in stroke rates, and it will still remain uncertain if rivaroxaban 2.5 mg b.i.d. would adequately reduce strokes in AF, even when combined with antiplatelet agents. A similar but larger clinical trial with dabigatran (RE-DUAL PCI) has also been announced (http://www. boehringer-ingelheim.com/news/news_releases/press_releases/2013/ 19_november_2013_dabigatranetexilate1.html).
Transcatheter aortic valve implantation
Parenteral antithrombotic treatment during TAVI aims to prevent thrombo-embolic complications related to large i.v. catheter manipulation, guidewire insertion, balloon aortic valvuloplasty and valve prosthesis implantation while minimizing the risk of bleeding particularly at the vascular access site.
Based on retrospective studies and randomized trials, 87 -91 the most commonly used anticoagulant is unfractionated heparin (UFH) at doses of 50-70 IU/kg with a target activated clotting time (ACT) of 250 -300 s, although no optimal ACT has been defined even in guidelines 92 -97 (Table 3 ). An alternative anticoagulant currently under investigation during TAVI is bivalirudin due to a favourable efficacy and safety profile compared with UFH during PCI.
98,99
The comparative safety of UFH and bivalirudin is the object of the ongoing Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3) trial (NCT01651780). Long-term oral antithrombotic treatment after TAVI aims to prevent complications notably ischaemic stroke and MI as well as thrombo-embolism related to deep vein thrombosis, pulmonary embolism, valve thrombosis, and embolism owing to AF while minimizing bleeding risk. The baseline risk for ischaemic and thrombo-embolic complications is determined by comorbidities including concomitant CAD which is present in 20 -70% of patients and requires PCI in 20-40% of patients. Furthermore, AF is found in about one-third of patients referred for TAVI. 88, 89, 100, 101 Prospective data on antithrombotic therapy after TAVI are scarce (Table 3) , and recommendations regarding pre-treatment, loading dose, and optimal duration of antiplatelet or antithrombotic therapy are largely based on experience from PCI and open-heart aortic valve replacement. Among patients without CAD and without AF, the current standard of care is dual antiplatelet therapy consisting of low-dose acetylsalicylic acid (75-100 mg per day) and clopidogrel 75 mg o.d. (after loading dose of 300-600 mg) for a variable period of time ranging from a minimum of 1 month to a maximum of 6 months followed by indefinite aspirin monotherapy. The ongoing Aspirin vs. aspirin + clopidogRel following Transcatheter aortic valve implantation (ARTE) pilot trial [NCT01559298 (http://clinicaltrials.gov/show/NCT01559298)] comparing single with dual antiplatelet therapy after TAVI will provide important information regarding the balance of ischaemic and bleeding risk associated with additional clopidogrel treatment.
Among TAVI patients with AF but without CAD, OAC is recommended in accordance with recommendations for AF alone. 11 Whether the addition of antiplatelet therapy to OAC is required in this context remains to be determined. The existing experience with patients receiving (biological) aortic valve replacement suggests that OAC alone may be sufficient to prevent thrombotic events. 93 Indeed, OAC (essentially VKAs) use in biological aortic valves (surgical implantation) is generally recommended for only 3 months and could be stopped thereafter, except where patients have other reasons for prolonged or life-long OAC.
In the absence of solid data sets for TAVI patients with AF and recent PCI, these patients should be treated similar to patients receiving a stent without TAVI. The use of new P2Y 12 inhibitors in combination with acetylsalicylic acid or NOAC after TAVI has not been investigated and cannot be recommended at this time.
In patients with artificial mechanical valves, NOACs should not be used. In the Phase 2 RE-ALIGN trial, 102 dabigatran was associated with more thrombo-embolism and major bleeding, compared with warfarin, leading to early cessation of the trial.
Peri-operative/periprocedural strategy in patients on antithrombotic combination therapy: a brief overview
Patients treated with VKAs have an increased risk of peri-and postprocedural bleeding complications when receiving active anticoagulation but surgery is usually safe as soon as the INR is ≤2.0. 103 On the other hand, prolonged discontinuation of VKAs is associated with an increased MACE rate, especially in patients at high risk for thromboembolic events. There is no sufficient evidence to support heparin bridging in anticoagulated patients in general. 104 Minor surgery can often be performed on continuous OAC. 19 If the peri-operative bleeding risk is moderate or high, VKAs should be discontinued between 3 and 5 days before surgery (dependent on the specific brand) with regular INR measurements. Surgery may be postponed if the INR is .2.0. Restarting VKA therapy depends on the individual peri-and post-operative bleeding risk and should be at the pre-procedural maintenance dose, and LMWH or UFH should be continued until the INR returns to therapeutic levels. 105 In surgical procedures with a low risk of bleeding (e.g.
cataract surgery, minor skin surgery, or minor dental surgery) VKA therapy can be maintained in patients with or without prior stroke. 104 In patients undergoing cardiac device implantation (see Supplementary material online, Table w4 ).
In patients treated with NOACs bridging to surgery is usually not necessary, due to the fast-onset and offset action of these agents. 126, 127 As a general recommendation, NOACs should be stopped 24 h before surgery in surgical interventions with low or 'normal' bleeding risk, and 48 h before surgery in surgical interventions with high-bleeding risk. 128 Patients with advanced chronic kidney disease may require longer stopping times, depending on the reliance of the NOAC on renal clearance. In the RE-LY study, dabigatran facilitated a shorter interruption of OAC in patients having urgent surgery, while rates of peri-procedural bleeding were similar in patients on dabigatran or warfarin, respectively.
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Whether continuation/administration of NOACs during left atrial catheter ablation is safe and effective is still a matter of debate, but recent meta-analyses have shown no differences in thromboembolism and bleeding between dabigatran and warfarin. 130, 131 Observational data with rivaroxaban also seem reassuring. 132 Prospective controlled trials are ongoing.
Limitations of the current data and future areas of research
While patients discussed in this document are likely to be in need of both OAC and antiplatelet therapy, an adequate balance between Antithrombotic management in atrial fibrillation patients with ACS/PCI Expert consensus document -TAVI -Recommendation for DAPT for 1 -6 months followed by indefinite ASA 100 -300 mg/day In case there is an indication for oral anticoagulation, triple therapy (,3 months) might be considered
Continued
Antithrombotic management in atrial fibrillation patients with ACS/PCI ischaemic stroke, bleeding risk, recurrent coronary events, and stent thrombosis will require some degree of personalized management. 133 There are adequate historic data to suggest that a combination of OAC and antiplatelet agents is able to prevent AF-related strokes, stent thrombosis, and recurrent coronary events. The suggestions for antithrombotic therapy put forward in this consensus document are largely based on expert consensus and/or derived from extrapolation of data from patients in sinus rhythm, observational studies, subgroup analyses, and a few smaller controlled trials. We have data for the bleeding effects of combination therapy in non-AF populations for dabigatran, 60 apixaban, 64 and rivaroxaban, 62, 134 although for rivaroxaban, this was generally at doses that are lower compared with those proven to provide stroke prevention in AF. Better assessment of bleeding and ischaemic risk in PCI patients with AF would be desirable. A sizeable proportion of the anticoagulated AF population will be in need for transient combination therapy of OAC with antiplatelet therapy. Continuation of an existing anticoagulant and addition of carefully weighed antiplatelet therapy seem reasonable in most patients, as outlined in this document. Unfortunately, there is a lack of adequately powered, outcome-based controlled trials comparing different antithrombotic regimes in patients with AF undergoing coronary stenting procedures and/or experiencing an ACS, and in those developing a need for OAC (i.e. AF) during or shortly after ACS.
The clinical outcomes of ACS patients differ markedly from stable patients with AF and CAD (e.g. in the risk for reinfarction or access site/periprocedural bleeding). Importantly, ACS patients are at a higher risk of stroke and reinfarction than stable patients with AF and CAD, and the mechanisms of thrombotic events in a clinical situation of activated inflammatory and prothrombotic signalling cascades may differ from stable patients.
Thus, there is a clear need for high-quality-controlled clinical trials to define the optimal antithrombotic therapy in these patients. The patient population in need for optimized therapy is rather large, and the event rates seem sufficiently high to make such trials feasible and sufficiently important for the cardiovascular community.
Also, there is increasing recognition that the quality of INR control (as reflected by average individual TTR) in a VKA-treated patient is closely related to efficacy and safety outcomes. 135 A low TTR is associated with a high risk of thrombo-embolism and serious bleeding, while a high TTR is associated with low-adverse event rates. 136, 137 A recent ESC anticoagulation working group position document 138 recommends a TTR of .70%, and such a 'high-TTR' anticoagulation strategy could be tested against 'usual care' in ACS patients with AF undergoing PCI/stenting. Also, a management strategy based on predicting those who would do well on a VKA with a high TTR, using a recently validated clinical score 139 [SAME-TT 2 R 2 score (SAME-TT 2 R 2 score: Sex (females), Age (,60 years), Medical history (at least two of the following: hypertension, diabetes, coronary artery disease/myocardial infarction, peripheral arterial disease, congestive heart failure, previous stroke, pulmonary disease, hepatic or renal disease), Treatment (interacting drugs, e.g. amiodarone for rhythm control) [all one point], as well as current Tobacco use (two points) and Race (non-Caucasian; two points)), e.g. 0-1] as recommended in the ESC anticoagulation consensus document, 138 could be tested against those where a VKA would be less suitable (with a high SAME-TT 2 R 2 score, e.g. ≥2) and a NOAC . (Grade 2C) ACT, activated clotting time; ASA, acetylsalicylic acid; DAPT, dual antiplatelet therapy; IV, intravenous; IU, International Units; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; THV, transcatheter heart valve; UFH, unfractionated heparin; VARC, Valve Academic Research Consortium; VKA, vitamin K antagonists.
would be a better alternative. The SAME-TT 2 R 2 score has recently been shown to be predictive of patients with poorer TTR levels, 140 and identifies those with labile INRs, and consequently, more thrombo-embolism and serious bleeding events. 141 Other areas in need of investigation via RCTs are listed below Until these studies are available, we will have to rely on more information from contemporary observational programmes. Such programmes will need adequate follow-up rates, good information on duration and type of therapy, and adequate adjudication of events to generate meaningful new information in addition to the available data sets.
Consensus recommendations
Consensus recommendations on the management of AF patients with ACS and/or undergoing PCI/stenting are summarized in Table 4 and Figure 1 .
In general, the period of triple therapy should be as short as possible, followed by OAC plus a single antiplatelet therapy (preferably clopidogrel 75 mg/day, or as an alternative, aspirin 75 -100 mg/day). The duration of triple therapy is dependent on a number of considerations: acute vs. elective procedures, bleeding risk (as assessed by the HAS-BLED score), type of stent (with a preference for new generation DES or BMS). In these consensus recommendations for patients with non-valvular AF, where we refer to OAC, this can either be with well-controlled adjusted dose VKA (with TTR .70%) or with a NOAC.
General
(i) In AF patients, stroke risk must be assessed using the CHA 2-DS 2 -VASc score, and bleeding risk assessed using the HAS-BLED score. 2 Risk stratification is a dynamic process, and must be performed at regular intervals (i.e. on a yearly basis) (Class I, level of evidence C).
(a) The HAS-BLED score should be used to 'flag up' the patients potentially at risk of bleeding, and to help identify and correct the potentially reversible bleeding risk factors (e.g. uncontrolled hypertension, labile INRs, concomitant use of aspirin or NSAIDs, alcohol excess/abuse, etc.). 2, 142 (b) Risk stratification for ACS should be performed using the GRACE score, as per current guidelines.
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(ii) Where adjusted dose VKA is used, good quality anticoagulation control is recommended, with a TTR .70% ( PPI should be considered in all patients, particularly where aspirin is used. Newer generation drug-eluting stents should be preferred over bare metal stents in patients at low risk for bleeding. New generation drug-eluting stent is generally preferable over bare-metal stent, particularly in patients at low bleeding risk (HAS-BLED 0-2). OAC, oral anticoagulation, either warfarin (INR: 2.0-2. 
NSTE-ACS including unstable angina and NSTEMI
(i) Patients with moderate-to-high-risk NSTE-ACS and AF at low risk of bleeding (HAS-BLED 0-2) should receive dual antiplatelet therapy with aspirin plus clopidogrel and OAC (i.e. whether NOAC or a VKA) should also be given/continued (Class IIa, level of evidence C). (ii) An early invasive strategy (within 24 h) should be preferred among patients with moderate-to-high-risk NSTE-ACS in Figure 1 Choice of antithrombotic therapy, including combination strategies of oral anticoagulation (O), aspirin (A) and/or clopidogrel (C). For
Step 4, background colour and gradients reflect the intensity of antithrombotic therapy (i.e. dark background colour ¼ high intensity; light background colour ¼ low intensity). Solid boxes represent recommended drugs. Dashed boxes represent optional drugs depending on clinical judgement. New generation drug-eluting stent is generally preferable over bare-metal stent, particularly in patients at low bleeding risk (HAS-BLED 0-2). When vitamin K antagonists are used as part of triple therapy, international normalized ratio should be targeted at 2.0 -2.5 and the time in the therapeutic range should be .70%. *Dual therapy with oral anticoagulation and clopidogrel may be considered in selected patients. **Aspirin as an alternative to clopidogrel may be considered in patients on dual therapy (i.e. oral anticoagulation plus single antiplatelet). ***Dual therapy with oral anticoagulation and an antiplatelet agent (aspirin or clopidogrel) may be considered in patients at very high risk of coronary events. ACS, acute coronary syndromes; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary intervention.
order to expedite treatment allocation (medical vs. PCI vs. CABG) and to determine the optimal antithrombotic regimen (Class IIa, level of evidence C). in a patient at low risk of bleeding, bivalirudin should be considered as alternative to unfractionated heparin (class IIa, level of evidence B). (iv) In patients with ACS and AF at low risk of bleeding (HAS-BLED 0-2), the initial use of triple therapy (OAC, aspirin, and clopidogrel) should be considered for 6 months following PCI irrespective of stent type; this should be followed by long-term therapy (up to 12 months) with OAC and clopidogrel 75 mg/ day (or alternatively, aspirin 75-100 mg/day) (Class IIa, level of evidence C).
(a) In selected patients with a CHA 2 DS 2 -VASc score ≥2 at low risk of bleeding (HAS-BLED 0-2), continuation of triple therapy or dual antiplatelet therapy consisting of OAC (i.e. whether NOAC or a VKA) and clopidogrel 75 mg/ day may be considered (Class IIb, level of evidence C) between 6 and 12 months (Class IIb, level of evidence C). (v) In patients with ACS and AF at high risk of bleeding (HAS-BLED ≥3), the initial use of triple therapy (OAC, aspirin, and clopidogrel) should be considered for 4 weeks following PCI irrespective of stent type; this should be followed by long-term therapy (up to 12 months) with OAC and a single antiplatelet drug (preferably clopidogrel 75 mg/day, or as an alternative, aspirin 75-100 mg/day) (Class IIa, level of evidence C).
(a) As an alternative to initial triple therapy in selected patients at high risk of bleeding (e.g. HAS-BLED ≥3) and low risk of stent thrombosis/recurrent ischaemic events, dual therapy consisting of OAC and clopidogrel 75 mg/day may be considered (Class IIb, level of evidence C Primary PCI (i) In the acute setting, a patient with AF and STEMI may be treated with primary PCI, aspirin, clopidogrel, and heparin (UFH) or bivalirudin, while GP IIb/IIIa inhibitors in bailout situations might be useful in some cases. Given the risk of bleeding with such combination antithrombotic therapies, it may sometimes be prudent to temporarily stop OAC therapy. Regular or even 'routine' use of GP IIb/IIIa inhibitors is discouraged, as are the novel P2Y 12 inhibitors (Class IIb, level of evidence B). (ii) In the setting of STEMI, radial access for primary PCI is the best option to avoid procedural bleeding depending on operator expertise and preference (Class I, level of evidence A). (iii) In patients with STEMI and AF at low risk of bleeding (HAS-BLED 0 -2), the initial use of triple therapy (OAC, aspirin, and clopidogrel) should be considered for 6 months following PCI irrespective of stent type; this should be followed by long-term therapy (up to 12 months) with OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day) (Class IIa, level of evidence C).
(a) In selected patients with STEMI and a CHA 2 DS 2 -VASc score ≥2 at low risk of bleeding (HAS-BLED 0-2), continuation of triple therapy or dual antiplatelet therapy consisting of OAC (i.e. whether NOAC or a VKA) and clopidogrel 75 mg/day may be considered (Class IIb, level of evidence C) between 6 and 12 months. (iv) In patients with STEMI and AF at high risk of bleeding (HAS-BLED ≥3), the initial use of triple therapy (OAC, aspirin, and clopidogrel) should be considered for 4 weeks following PCI irrespective of stent type; this should be followed by long-term therapy (up to 12 months) with OAC and clopidogrel 75 mg/day (or alternatively, aspirin 75-100 mg/day) (Class IIa, level of evidence C).
(a) As an alternative to the initial triple therapy in selected patients at high risk of bleeding (e.g. HAS-BLED ≥3) and low risk of stent thrombosis/recurrent ischaemic events, dual therapy consisting of OAC and clopidogrel 75 mg/ day may be considered (Class IIb, level of evidence B). (a) The use of ticagrelor or prasugrel in combination with OAC may only be considered under very circumstances (e.g. definite stent thrombosis while on clopidogrel, aspirin, and OAC) (Class IIb, level of evidence C).
Application to general anticoagulated patients, who may or may not have AF
The recommendations for non-valvular AF patients largely apply to 'general' anticoagulated populations, with some notable exceptions.
(i) Where patients have AF and a prosthetic mechanical heart valve, such patients would be at substantial risk of thromboembolism and/or prosthetic valve thrombosis during interruption of anticoagulation using a VKA. These patients should undergo percutaneous procedures during anticoagulation with VKA with the lowest possible median INR within the therapeutic range based on risk factors and prosthesis thrombogenicity (Class IIa, level of evidence B). 
